Pulmonary exposure to single-walled carbon nanotubes does not affect the early immune response against Toxoplasma gondii

Particle and Fibre Toxicology

Volumn 9, Issue , 2012, Pages

  Swedin, Linda ^a   Arrighi, Romanico ^a,b   Andersson Willman, Britta ^a   Murray, Ashley ^c,d   Chen, Yunying ^a   Karlsson, Mikael C I ^a   Georén, Susanna Kumlien ^a   Tkach, Alexey V ^c   Shvedova, Anna A ^c,d   Fadeel, Bengt ^a   Barragan, Antonio ^a,b   Scheynius, Annika ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Swedish Institute for Communicable Disease Control   (Sweden)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^d WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioluminescence imaging; Carbon nanotubes; Dendritic cells; Inflammation markers; Lung and spleen immunohistology; Macrophages; Toxoplasma gondii

Indexed keywords

ANTIGEN; F4 ANTIGEN; GLYCOPROTEIN P 15095; GREEN FLUORESCENT PROTEIN; LUCIFERASE; SINGLE WALLED NANOTUBE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; C57BL 6 MOUSE; CELLULAR STRESS RESPONSE; DENDRITIC CELL; FEMALE; HISTOPATHOLOGY; HOST PARASITE INTERACTION; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LUNG; LUNG LAVAGE; MACROPHAGE; MOUSE; NASOPHARYNGEAL ASPIRATION; NONHUMAN; PARASITE LOAD; PARASITE MIGRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; SPLEEN CELL; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; IMMUNITY, CELLULAR; INTUBATION, INTRATRACHEAL; LUNG; MICE; MICE, INBRED C57BL; NANOTUBES, CARBON; PNEUMONIA; PULMONARY FIBROSIS; SPLEEN; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

MUS; TOXOPLASMA GONDII;

EID: 84861330327     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/1743-8977-9-16     Document Type: Article

References (35)

1. Shvedova AA, Kisin ER, Porter D, Schulte P, Kagan VE, Fadeel B, Castranova V. Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus?. Pharmacol Ther 2009, 121(2):192-204. 10.1016/j.pharmthera.2008.10.009, 19103221.
2. Shvedova AA, Fabisiak JP, Kisin ER, Murray AR, Roberts JR, Tyurina YY, Antonini JM, Feng WH, Kommineni C, Reynolds J, et al. Sequential exposure to carbon nanotubes and bacteria enhances pulmonary inflammation and infectivity. Am J Respir Cell Mol Biol 2008, 38(5):579-590. 2335338, 18096873.
3. Shvedova AA, Kisin ER, Mercer R, Murray AR, Johnson VJ, Potapovich AI, Tyurina YY, Gorelik O, Arepalli S, Schwegler-Berry D, et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol 2005, 289(5):L698-L708. 10.1152/ajplung.00084.2005, 15951334.
4. Mitchell LA, Gao J, Wal RV, Gigliotti A, Burchiel SW, McDonald JD. Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes. Toxicol Sci 2007, 100(1):203-214. 10.1093/toxsci/kfm196, 17660506.
5. Mitchell LA, Lauer FT, Burchiel SW, McDonald JD. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat Nanotechnol 2009, 4(7):451-456. 10.1038/nnano.2009.151, 19581899.
6. Joynson DH, Wreghitt TJ. Toxoplasmosis: a comprehensive clinical guide 2001, Cambridge, UK: Cambridge University Press.
7. Luft BJ, Hafner R, Korzun AH, Leport C, Antoniskis D, Bosler EM, Luft BJ, Hafner R, Korzun AH, Leport C, Antoniskis D, Bosler EM, Bourland DD, Uttamchandani R, Fuhrer J, Jacobson J, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med 1993, 329(14):995-1000. 10.1056/NEJM199309303291403, 8366923.
8. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004, 363(9425):1965-1976. 10.1016/S0140-6736(04)16412-X, 15194258.
9. Evans TG, Schwartzman JD. Pulmonary toxoplasmosis. Semin Respir Infect 1991, 6(1):51-57.
10. Huang L, Crothers K. HIV-associated opportunistic pneumonias. Respirology 2009, 14(4):474-485. 10.1111/j.1440-1843.2009.01534.x, 2835537, 19645867.
11. Murray JF, Felton CP, Garay SM, Gottlieb MS, Hopewell PC, Stover DE, Teirstein AS. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop. N Engl J Med 1984, 310(25):1682-1688. 10.1056/NEJM198406213102529, 6328301.
12. Sacks D, Sher A. Evasion of innate immunity by parasitic protozoa. Nat Immunol 2002, 3(11):1041-1047. 10.1038/ni1102-1041, 12407413.
13. Yap GS, Sher A. Effector cells of both nonhemopoietic and hemopoietic origin are required for interferon (IFN)-gamma- and tumor necrosis factor (TNF)-alpha-dependent host resistance to the intracellular pathogen, Toxoplasma gondii. J Exp Med 1999, 189(7):1083-1092. 10.1084/jem.189.7.1083, 2192999, 10190899.
14. Courret N, Darche S, Sonigo P, Milon G, Buzoni-Gatel D, Tardieux I. CD11c-and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood 2006, 107(1):309-316. 10.1182/blood-2005-02-0666, 1895351, 16051744.
15. Lambert H, Barragan A. Modelling parasite dissemination: host cell subversion and immune evasion by Toxoplasma gondii. Cell Microbiol 2010, 12(3):292-300. 10.1111/j.1462-5822.2009.01417.x, 19995386.
16. Lambert H, Hitziger N, Dellacasa I, Svensson M, Barragan A. Induction ofdendritic cell migration upon Toxoplasma gondii infection potentiates parasite dissemination. Cell Microbiol 2006, 8(10):1611-1623. 10.1111/j.1462-5822.2006.00735.x, 16984416.
17. Hitziger N, Dellacasa I, Albiger B, Barragan A. Dissemination of Toxoplasma gondii to immunoprivileged organs and role of Toll/interleukin-1 receptor signalling for host resistance assessed by in vivo bioluminescence imaging. Cell Microbiol 2005, 7(6):837-848. 10.1111/j.1462-5822.2005.00517.x, 15888086.
18. Saeij JP, Boyle JP, Grigg ME, Arrizabalaga G, Boothroyd JC. Bioluminescence imaging of Toxoplasma gondii infection in living mice reveals dramatic differences between strains. Infect Immun 2005, 73(2):695-702. 10.1128/IAI.73.2.695-702.2005, 547072, 15664907.
19. Candolfi E, Hunter CA, Remington JS. Roles of gamma interferon and other cytokines in suppression of the spleen cell proliferative response to concanavalin A and toxoplasma antigen during acute toxoplasmosis. Infect Immun 1995, 63(3):751-756. 173066, 7868243.
20. Fenoy I, Giovannoni M, Batalla E, Martin V, Frank FM, Piazzon I, Goldman A. Toxoplasma gondii infection blocks the development of allergic airway inflammation in BALB/c mice. Clin Exp Immunol 2009, 155:275-284. 10.1111/j.1365-2249.2008.03813.x, 2675259, 19032550.
21. Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH, Lee JH. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci 2007, 22:S38-S46. 10.3346/jkms.2007.22.S.S38, 2694397, 17923753.
22. O'Brien KB, Schultz-Cherry S, Knoll LJ. Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection. J Virol 2011, 85:8680-8688. 10.1128/JVI.05142-11, 3165849, 21734055.
23. Tkach AV, Shurin GV, Shurin MR, Kisin ER, Murray AR, Young SH, Star A, Fadeel B, Kagan VE, Shvedova AA. Direct Effects of Carbon Nanotubes onDendritic Cells Induce Immune Suppression Upon Pulmonary Exposure. ACS Nano 2011, 5(7):5755-5762. 10.1021/nn2014479, 3170729, 21657201.
24. Barragan A, Hitziger N. Transepithelial migration by Toxoplasma. Subcell Biochem 2008, 47:198-207. 10.1007/978-0-387-78267-6_16, 18512353.
25. Channon JY, Seguin RM, Kasper LH. Differential infectivity and division of Toxoplasma gondii in human peripheral blood leukocytes. Infect Immun 2000, 68(8):4822-4826. 10.1128/IAI.68.8.4822-4826.2000, 98447, 10899898.
26. Aliberti J. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat Rev Immunol 2005, 5(2):162-170. 10.1038/nri1547, 15662369.
27. Liu CH, Fan YT, Dias A, Esper L, Corn RA, Bafica A, Machado FS, Aliberti J. Cutting edge: dendritic cells are essential for in vivo IL-12 production and development of resistance against Toxoplasma gondii infection in mice. J Immunol 2006, 177(1):31-35.
28. McKee AS, Dzierszinski F, Boes M, Roos DS, Pearce EJ. Functional inactivation of immature dendritic cells by the intracellular parasite Toxoplasma gondii. J Immunol 2004, 173(4):2632-2640.
29. Pepper M, Dzierszinski F, Wilson E, Tait E, Fang Q, Yarovinsky F, Laufer TM, Roos D, Hunter CA. Plasmacytoid dendritic cells are activated by Toxoplasma gondii to present antigen and produce cytokines. J Immunol 2008, 180(9):6229-6236.
30. Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, Germain RN, Sher A. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med 1997, 186(11):1819-1829. 10.1084/jem.186.11.1819, 2199158, 9382881.
31. Blader IJ, Saeij JP. Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence. APMIS 2009, 117(5-6):458-476. 2810527, 19400868.
32. Munoz M, Liesenfeld O, Heimesaat MM. Immunology of Toxoplasmagondii. Immunol Rev 2011, 240(1):269-285. 10.1111/j.1600-065X.2010.00992.x, 21349099.
33. Wei S, Marches F, Borvak J, Zou W, Channon J, White M, Radke J, Cesbron-Delauw MF, Curiel TJ. Toxoplasma gondii-infected human myeloid dendritic cells induce T-lymphocyte dysfunction and contact-dependent apoptosis. Infect Immun 2002, 70(4):1750-1760. 10.1128/IAI.70.4.1750-1760.2002, 127822, 11895936.
34. Mordue DG, Monroy F, La Regina M, Dinarello CA, Sibley LD. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J Immunol 2001, 167(8):4574-4584.
35. Sharma SD, Mullenax J, Araujo FG, Erlich HA, Remington JS. Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol 1983, 131(2):977-983.